{"protocolSection":{"identificationModule":{"nctId":"NCT06196398","orgStudyIdInfo":{"id":"XWFFR-3"},"organization":{"fullName":"Xuanwu Hospital, Beijing","class":"OTHER"},"briefTitle":"Effects of Medical Treatment of ICAS With Hemodynamic Disorders Based on MR-FFR","officialTitle":"Effects of Medical Treatment of Intracranial Atherosclerotic Diseases Based on Magnetic Resonance Fractional Flow Reserve"},"statusModule":{"statusVerifiedDate":"2023-12","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-01-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2024-06","type":"ESTIMATED"},"completionDateStruct":{"date":"2024-06","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-12-25","studyFirstSubmitQcDate":"2023-12-25","studyFirstPostDateStruct":{"date":"2024-01-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-12-25","lastUpdatePostDateStruct":{"date":"2024-01-09","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Xuanwu Hospital, Beijing","class":"OTHER"},"collaborators":[{"name":"National Key Research and Development Project, China","class":"UNKNOWN"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This multicenter prospective cohort study aims to compare the difference in the effects of medical treatment within 1 year between the two groups of ICAS patients divided hemodynamically by Magnetic Resonance Fractional Flow Reserve. PC MRA will be applied for FFR measurement. The primary outcome is the composite of ischemic stroke or death related to the qualifying artery territory for 1 year."},"conditionsModule":{"conditions":["Stroke, Ischemic","Intracranial Atherosclerosis"],"keywords":["Intracranial atherosclerotic diseases","Fractional Flow Reserve","Hemodynamics","Stroke"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"COHORT","timePerspective":"PROSPECTIVE"},"enrollmentInfo":{"count":400,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Decompensated blood flow reserve","description":"ICAS patients with decompensated cerebral blood flow reserve diagnosed by MR-FFR (FFR baseline≥0.81).","interventionNames":["Drug: Standard Medical Treatment on the basis of anti-platelet therapy"]},{"label":"Normal blood flow reserve","description":"ICAS patients with normal cerebral blood flow reserve determined by MR-FFR (FFR baseline\\<0.81).","interventionNames":["Drug: Standard Medical Treatment on the basis of anti-platelet therapy"]}],"interventions":[{"type":"DRUG","name":"Standard Medical Treatment on the basis of anti-platelet therapy","description":"1. Anti-platelet therapy: aspirin 75mg+clopidogrel 100mg will be applied for patients with severe ICAS stenosis (70%-90%) suffering stroke or TIA within 30 days. After 90 days, single anti-platelet therapy will be continued.\n2. Intensive statin therapy: Statins with high doses\n3. Blood pressure: below 140/90mmHg\n4. LDL: less than 1.81mmol/L(70mg/dl)\n5. Fasting blood glucose controlled to 5.9mmol/L, and glycosylated hemoglobin A1c reduced to less than 7%\n6. Cigarette and alcohol quitting\n7. Oral anticoagulants for atrial fibrillation","armGroupLabels":["Decompensated blood flow reserve","Normal blood flow reserve"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"The composite of ischemic stroke or death related to the qualifying artery territory","timeFrame":"1 year"}],"secondaryOutcomes":[{"measure":"Functional evaluation","description":"Modified Rankin Scale score","timeFrame":"1 year"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Patients aged from 30 to 80 with symptomatic ICAS lesion in anterior circulation.\n2. 50% to 99% stenosis (in accordance with modified WASID method) confirmed by DSA, CTA or MRA.\n3. mRS 0-2 points\n4. Informed of the study protocol and objectives.\n\nExclusion Criteria:\n\n1. Previous endovascular treatment or surgery for cerebrovascular diseases\n2. Large cerebral infarction (more than 1/2 MCA perfusion area) according to MRI\n3. Combined with other neurological diseases, such as aneurysm, arteriovenous malformation, tumor, hydrocephalus, cerebral trauma, cerebral hemorrhage, multiple sclerosis, epilepsy and intracranial infection.\n4. Pregnancy or in the preparation for pregnancy\n5. Patients who cannot tolerate or do not allow MR screening, including metal implanting and claustrophobia\n6. Contraindication for antiplatelet drugs or statins\n7. Patients with severe dementia or mental disorders, who cannot cooperate with examination","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Patients with symptomatic, moderate to severe stenosis of major arteries in intracranial anterior circulation. The stenosis degree is ≥ 50%, confirmed by imaging evidence, according to modified WASID criteria.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"centralContacts":[{"name":"Jichang Luo","role":"CONTACT","phone":"+8613120136577","email":"luojichang_dr@sina.com"}],"locations":[{"facility":"Xuanwu Hospital, Capital Medical University","status":"RECRUITING","city":"Beijing","state":"Beijing","country":"China","contacts":[{"name":"Jichang Luo","role":"CONTACT","email":"luojichang_dr@sina.com"}],"geoPoint":{"lat":39.9075,"lon":116.39723}}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002537","term":"Intracranial Arteriosclerosis"},{"id":"D000050197","term":"Atherosclerosis"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000001161","term":"Arteriosclerosis"},{"id":"D000001157","term":"Arterial Occlusive Diseases"},{"id":"D000020765","term":"Intracranial Arterial Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M25878","name":"Atherosclerosis","asFound":"Atherosclerosis","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Stroke, Ischemic","relevance":"HIGH"},{"id":"M5476","name":"Intracranial Arteriosclerosis","asFound":"Intracranial Atherosclerosis","relevance":"HIGH"},{"id":"M4159","name":"Arteriosclerosis","relevance":"LOW"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M4155","name":"Arterial Occlusive Diseases","relevance":"LOW"},{"id":"M22211","name":"Intracranial Arterial Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M3467","name":"Ethanol","relevance":"LOW"},{"id":"M4238","name":"Aspirin","relevance":"LOW"},{"id":"M1669","name":"Clopidogrel","relevance":"LOW"},{"id":"M207468","name":"Chrysarobin","relevance":"LOW"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M20845","name":"Hydroxymethylglutaryl-CoA Reductase Inhibitors","relevance":"LOW"}],"browseBranches":[{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"CNSDep","name":"Central Nervous System Depressants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Antipy","name":"Antipyretics"},{"abbrev":"Infl","name":"Anti-Inflammatory Agents"},{"abbrev":"ARhu","name":"Antirheumatic Agents"},{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"Analg","name":"Analgesics"},{"abbrev":"PlAggInh","name":"Platelet Aggregation Inhibitors"},{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"Lipd","name":"Lipid Regulating Agents"}]}},"hasResults":false}